TriSalus (TLSI) director Matlin receives RSU and option grants for 2026 service

(Neutral)

Form Type

Rhea-AI Filing Summary

TriSalus Life Sciences director David J. Matlin reported equity compensation grants. He received 23,065 restricted stock units that vest in full on the one-year anniversary of the May 14, 2026 grant date, subject to continued service.

He also received 28,201 restricted stock units in lieu of 2026 board service retainer cash fees; these vest in three equal quarterly installments through the remainder of 2026, subject to continued service. In addition, he was granted options to purchase 56,403 shares of common stock at an exercise price of $2.52 per share, vesting in full on the one-year anniversary of the May 14, 2026 grant date. Following these awards, Matlin directly holds 1,323,210 shares of common stock and 121,403 stock options.

Insider Trade Summary

Net Buyer: 51,266 shares

Net Buy 3 txns

Insider MATLIN DAVID J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (right to buy)	56,403	$0.00	$0.00
Grant/Award	Common Stock	28,201	$0.00	$0.00
Grant/Award	Common Stock	23,065	$0.00	$0.00

Holdings After Transaction: Director Stock Option (right to buy) — 121,403 shares (Direct); Common Stock — 1,323,210 shares (Direct)

Footnotes (3)

F1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.
F2. Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer.
F3. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

Key Figures

RSU Award: 23,065 shares Retainer RSU Award: 28,201 shares Director stock option grant: 56,403 options at $2.52/share +2 more

5 metrics

RSU Award 23,065 shares Restricted stock units vesting one year after May 14, 2026

Retainer RSU Award 28,201 shares RSUs in lieu of 2026 board retainer, vesting quarterly in 2026

Director stock option grant 56,403 options at $2.52/share Options vest one year after May 14, 2026; expire May 13, 2036

Common shares held 1,323,210 shares Total TriSalus common stock directly held after reported grants

Options held after grants 121,403 options Total director stock options directly held after the new award

Key Terms

restricted stock units, Retainer RSU Award, Non-Employee Director Compensation Policy, Director Stock Option, +1 more

5 terms

restricted stock units financial

"Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Retainer RSU Award financial

"Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer."

Non-Employee Director Compensation Policy financial

"retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy."

Director Stock Option financial

"Director Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price": "2.5200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/15/2026 - 04:39 PM

FAQ

What did TriSalus (TLSI) director David J. Matlin report in this Form 4?

David J. Matlin reported equity compensation grants, not open-market trades. He received two restricted stock unit awards and a stock option grant, all tied to his 2026 board service and subject to vesting based on continued service with TriSalus Life Sciences.

How many TriSalus (TLSI) restricted stock units were granted to David J. Matlin?

Matlin received 23,065 restricted stock units under an RSU Award and 28,201 restricted stock units as a Retainer RSU Award. Both are payable solely in common stock, with distinct vesting schedules linked to his ongoing service as a non-employee director in 2026.

What are the terms of David J. Matlin’s TriSalus (TLSI) director stock option grant?

Matlin was granted options for 56,403 shares of TriSalus common stock at an exercise price of $2.52 per share. These options vest in full on the one-year anniversary of the May 14, 2026 grant date and expire on May 13, 2036, assuming continued service.

Why did David J. Matlin receive a Retainer RSU Award from TriSalus (TLSI)?

Matlin elected to receive his 2026 board service retainer in stock instead of cash. The Retainer RSU Award of 28,201 restricted stock units replaces cash retainer fees and will vest in three equal quarterly installments over the remainder of 2026, contingent on continued service.

How many TriSalus (TLSI) shares does David J. Matlin hold after these grants?

After the reported transactions, Matlin directly holds 1,323,210 shares of TriSalus common stock. He also holds 121,403 stock options in total, including the newly granted 56,403 options, reflecting his ongoing equity-based alignment with the company’s performance.

Are David J. Matlin’s TriSalus (TLSI) awards immediately vested?

No, the awards are subject to vesting. The 23,065 RSUs and 56,403 options each vest fully on the one-year anniversary of the May 14, 2026 grant date, while the 28,201 Retainer RSUs vest in three equal quarterly installments during the remainder of 2026.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MATLIN DAVID J

(Last)

(First)

(Middle)

6272 W. 91ST AVENUE

(Street)

WESTMINSTER

COLORADO

80031

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TriSalus Life Sciences, Inc. [ TLSI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/14/2026		A		28,201⁽¹⁾	A	$0	1,300,145	D
Common Stock	05/14/2026		A		23,065⁽²⁾	A	$0	1,323,210	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Director Stock Option (right to buy)	$2.52	05/14/2026		A		56,403		⁽³⁾	05/13/2036	Common Stock	56,403	$0	121,403	D

Explanation of Responses:

1. Represents grant of restricted stock units (the "RSU Award") payable solely in common stock of the Issuer. The shares subject to the RSU award shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

2. Represents grant of restricted stock units (the "Retainer RSU Award") payable solely in common stock of the Issuer. The Reporting Person elected to receive the Retainer RSU Award in lieu of 2026 board service retainer cash fees provided for under the Issuer's Non-Employee Director Compensation Policy. The shares subject to the Retainer RSU Award shall vest quarterly in equal one-third installments through the remainder of 2026, subject to the Reporting Person's continued service with the Issuer.

3. The shares subject to the option shall fully vest on the one-year anniversary of the grant date of May 14, 2026, subject to the Reporting Person's continued service with the Issuer.

Remarks:

	/s/ Mary Szela, Attorney-in-Fact	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR